Shanghai Ruijin Hospital recently announced multiple latest clinical research findings in the fields of endocrinology and hematology. The data show that novel targeted drugs and immunotherapy regimens have achieved breakthrough progress in the treatment of refractory leukemia and diabetic complications. The related papers have been published in authoritative international journals such as the *New England Journal of Medicine*, receiving high praise from international peers.
Among these, a novel dual-target inhibitor for acute myeloid leukemia demonstrated an 80% complete remission rate in phase I/II clinical trials, significantly outperforming traditional chemotherapy regimens. In the field of endocrinology, Ruijin Hospital's early screening technology for diabetic peripheral neuropathy, which utilizes artificial intelligence-based fundus analysis, has improved diagnostic accuracy to over 95%. This achievement has been adopted by the International Diabetes Federation as a recommended standard.
Background and Significance
As a top-tier comprehensive hospital in China, Ruijin Hospital's Department of Endocrinology and Department of Hematology have long ranked among the nation's leading departments. The data released this time not only reflect the hospital's deep investment in translational medicine research but also showcase the innovative capabilities of Chinese scholars in addressing global health challenges. Behind this international recognition lies the integrated "clinical-research-translation" platform established by Ruijin Hospital in recent years, supported by large-scale biobanks and gene sequencing infrastructure, enabling rapid validation and promotion of precision medicine strategies.
Significance for International Patients
For international patients, these advancements mean more precise diagnostic tools and more effective treatment options. For example, the novel targeted drugs offer new hope for leukemia patients who are resistant to conventional therapies, while the early screening technology for diabetic complications helps patients receive intervention before irreversible damage occurs. Additionally, Ruijin Hospital has opened an international patient channel, providing multilingual services and convenient remote consultations, allowing overseas patients to benefit from these cutting-edge achievements in a timely manner.
How MedCare Can Help
As a cross-border medical service platform, MedCare has established an official partnership with Ruijin Hospital, offering international patients end-to-end support from cost estimation to medical services, including scheduling specialist consultations, coordinating inpatient treatment, arranging translation accompaniment, and follow-up care. Our team is familiar with Ruijin Hospital's procedures and can help patients efficiently access the evaluation and implementation of these novel therapies. If you wish to learn more about Ruijin Hospital's latest research or treatment information, feel free to contact us.
Related reading: Overview of Partner Hospitals in Shanghai